HIGHLIGHTS
- who: Forum Discussion+ et al. from the University of Vienna, Fred Hutch, Janssen, Merck and Co, Inc, Kenilworth, NJ, USA, SMC have published the article: Type I error Considerations in Master Protocols with Common Control in Oncology, in the Journal: (JOURNAL)
- what: In the next section the authors report the summary of the discussions.
- how: The discussions focused on whether Type I error adjustments are necessary in a randomized oncology clinical trial under a Master protocol that is designed to evaluate multiple treatments versus a common control.
- future: Randomized studies are . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.